IPF is a devastating disease where patients lose 2%-5% of their lung function every single month!
For 65% of the patients who used Algernon Pharmaceuticals (CSE: AGN)'s Ifenprodil during the 12-week trial... their lung function either improved or remained stable!
No other biotech company with a drug at this stage of development has shown this!
All Bellus Health (BLU) and Trevi Therapeutics (TRVI) have done is reduce cough counts.
AGN's Ifenprodil reduces cough counts AND stops people's lung fibrosis from getting worse!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.